Robert T Keenan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3516655/publications.pdf

Version: 2024-02-01

37 papers	1,211 citations	471509 17 h-index	377865 34 g-index
38 all docs	38 docs citations	38 times ranked	1432 citing authors

#	Article	IF	Citations
1	Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout. Journal of Rheumatology, 2012, 39, 1458-1464.	2.0	173
2	Prevalence of Contraindications and Prescription of Pharmacologic Therapies for Gout. American Journal of Medicine, 2011, 124, 155-163.	1.5	168
3	Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases, 2017, 76, 811-820.	0.9	141
4	The biology of urate. Seminars in Arthritis and Rheumatism, 2020, 50, S2-S10.	3.4	82
5	Gout, Hyperuricemia, and Crystalâ€Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care and Research, 2019, 71, 427-434.	3.4	73
6	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.9	72
7	Gout, Hyperuricemia, and the Risk of Cardiovascular Disease: Cause and Effect?. Current Rheumatology Reports, 2010, 12, 118-124.	4.7	45
8	A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. Arthritis and Rheumatology, 2021, 73, 1533-1542.	5.6	45
9	Gout and its comorbidities. Bulletin of the NYU Hospital for Joint Diseases, 2010, 68, 199-203.	0.7	42
10	Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. Clinical Therapeutics, 2017, 39, 430-441.	2.5	34
11	An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. American Heart Journal, 2017, 187, 53-61.	2.7	33
12	Association of Gout With Longâ€Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease. Journal of the American Heart Association, 2018, 7, e009328.	3.7	32
13	Genetics of Hyperuricemia and Gout: Implications for the Present and Future. Current Rheumatology Reports, 2013, 15, 309.	4.7	31
14	Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking. Clinical Rheumatology, 2017, 36, 2101-2107.	2.2	26
15	Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout. Seminars in Arthritis and Rheumatism, 2017, 46, 754-758.	3.4	26
16	The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Seminars in Arthritis and Rheumatism, 2021, 51, 347-352.	3.4	26
17	RS3PE Presenting in a Unilateral Pattern: Case Report and Review of the Literature. Seminars in Arthritis and Rheumatism, 2009, 38, 428-433.	3.4	23
18	Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase. Rheumatology and Therapy, 2019, 6, 299-304.	2.3	17

#	Article	IF	Citations
19	Safety of Urate-Lowering Therapies. Rheumatic Disease Clinics of North America, 2012, 38, 663-680.	1.9	16
20	New and Pipeline Drugs for Gout. Current Rheumatology Reports, 2016, 18, 32.	4.7	15
21	Moving the Needle: Improving the Care of the Gout Patient. Rheumatology and Therapy, 2019, 6, 179-193.	2.3	14
22	The role of cystoid macular edema as a marker in the progression of non-paraneoplastic autoimmune retinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1867-1873.	1.9	11
23	SARILUMAB FOR RECALCITRANT CYSTOID MACULAR EDEMA IN NON-PARANEOPLASTIC AUTOIMMUNE RETINOPATHY. Retinal Cases and Brief Reports, 2019, Publish Ahead of Print, 504-508.	0.6	10
24	Update on the management of hyperuricemia and gout. Bulletin of the NYU Hospital for Joint Diseases, 2008, 66, 231-9.	0.7	10
25	Hyperuricemia, gout, and cardiovascular disease--an important "muddle". Bulletin of the NYU Hospital for Joint Diseases, 2009, 67, 285-90.	0.7	8
26	RECONSTITUTION OF THE ELLIPSOID ZONE WITH TOCILIZUMAB IN AUTOIMMUNE RETINOPATHY. Retinal Cases and Brief Reports, 2020, 14, 297-300.	0.6	7
27	Inpatient Gout: A Review. Current Rheumatology Reports, 2014, 16, 458.	4.7	4
28	Current and Emerging Therapies for Gout. Current Treatment Options in Rheumatology, 2015, 1, 143-155.	1.4	4
29	Etiology and Pathogenesis of Hyperuricemia and Gout. , 2017, , 1597-1619.e6.		4
30	Colorectal Cancer Among Gout Patients Undergoing Colonoscopy. Journal of Clinical Rheumatology, 2019, 25, 335-340.	0.9	4
31	Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response. Current Rheumatology Reports, 2022, 24, 12-19.	4.7	4
32	Febuxostat: A new agent for lowering serum urate. Drugs of Today, 2009, 45, 247.	1.1	4
33	CaseBook Challenges: Managing Gout, Hyperuricemia and Comorbiditiesâ€"Dialogue with the Experts. American Journal of Medicine, 2014, 127, S1.	1.5	3
34	Antiâ€"Interleukin-6 Antibodies for Autoimmune Retinopathy with Macular Edema. Ophthalmology Retina, 2022, 6, 91-93.	2.4	3
35	Is It Time for Gout Flare Treatment to Move into the 21st Century?. Journal of Rheumatology, 2019, 46, 667-669.	2.0	1
36	Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels. Clinical and Experimental Rheumatology, 0, , .	0.8	0

#	Article	IF	Citations
37	Pegloticase causes prolonged improvement in multiple disease parameters in patients with chronic refractory gout who maintain low serum urate levels.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0